TORONTO, Jan. 6, 2016 /CNW/ - Transition
Therapeutics Inc. ("Transition" or the "Company") (NASDAQ:
TTHI, TSX: TTH) announces that the following five directors were
elected at the Annual General Meeting of shareholders of the
Company held on December 10, 2015
(the "Meeting"):
|
NOMINEE
|
VOTES IN
FAVOR
|
%
|
VOTES
WITHHELD
|
%
|
|
Michael
Ashton
|
18,526,595
|
98.92%
|
202,544
|
1.08%
|
|
Paul Baehr
|
18,527,206
|
98.92%
|
201,933
|
1.08%
|
|
Dr. Tony
Cruz
|
18,534,229
|
98.96%
|
194,910
|
1.04%
|
|
Christopher M.
Henley
|
18,527,573
|
98.92%
|
201,566
|
1.08%
|
|
Dr. Gary W.
Pace
|
18,526,672
|
98.92%
|
202,467
|
1.08%
|
The formal report of voting results with respect
to all matters voted upon at the Meeting was filed on SEDAR on
December 11, 2015.
About Transition
Transition is a biopharmaceutical company,
developing novel therapeutics for disease indications with large
markets. The Company's lead CNS drug candidate is ELND005 for the
treatment of Alzheimer's disease and Down syndrome.
Transition's lead metabolic drug candidate is TT-401 (LY2944876)
for the treatment of type 2 diabetes and accompanying obesity. The
Company's shares are listed on the NASDAQ under the symbol "TTHI"
and the Toronto Stock Exchange under the symbol "TTH". For
additional information about the Company, please visit
www.transitiontherapeutics.com.
Notice to Readers: Information contained in our
press releases should be considered accurate only as of the date of
the release and may be superseded by more recent information we
have disclosed in later press releases, filings with the OSC, SEC
or otherwise. Except for historical information, this press release
may contain forward-looking statements, relating to expectations,
plans or prospects for Transition, including conducting clinical
trials and potential efficacy of its products. These statements are
based upon the current expectations and beliefs of Transition's
management and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those
described in the forward-looking statements. These risks and
uncertainties include factors beyond Transition's control and the
risk factors and other cautionary statements discussed in
Transition's quarterly and annual filings with the Canadian
commissions.
SOURCE Transition Therapeutics Inc.